BNTX
BioNTech SENASDAQHealthcare$91.18+1.97%ClosedMarket Cap: $22.92B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.99
P/S
6.80
EV/EBITDA
-18.97
DCF Value
$47.65
FCF Yield
-1.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.7%
Operating Margin
-45.9%
Net Margin
-39.6%
ROE
-6.0%
ROA
-5.2%
ROIC
-6.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $898.9M | 63.3% | $-230.6M | $-302.1M | $-1.23 | — |
| FY 2025 | $2.76B | 77.6% | $-623.9M | $-1.09B | $-4.51 | — |
| Q3 2025 | $1.52B | 90.2% | $-46.9M | $-28.7M | $-0.12 | — |
| Q2 2025 | $260.8M | 70.7% | $-501.1M | $-386.6M | $-1.60 | — |
| Q1 2025 | $182.8M | 54.2% | $-534.1M | $-415.8M | $-1.73 | — |
| Q4 2024 | $1.19B | 79.5% | $148.6M | $259.5M | $1.08 | — |
| FY 2024 | $2.75B | 80.3% | $-1.31B | $-665.3M | $-2.77 | — |
| Q3 2024 | $1.24B | 85.6% | $10.5M | $198.1M | $0.81 | — |
| Q2 2024 | $128.7M | 53.5% | $-966.2M | $-807.8M | $-3.42 | — |
| Q1 2024 | $187.6M | 68.5% | $-507.2M | $-315.1M | $-1.31 | — |
| Q4 2023 | $1.48B | 87.9% | $526.2M | $457.9M | $1.84 | — |
| FY 2023 | $3.82B | 84.3% | $690.4M | $930.3M | $3.83 | — |